Elvia Cowan - 02 Nov 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: SVP, Finance & CAO
Issuer ticker: PCVX
Reported as of: 02 Nov 2026
Net transaction value: -$182,753
SEC form: 4
Accepted by SEC: 04 Nov 2026, 16:52:20 UTC
Prior SEC filing: 07 Oct 2026
Source filing: View source filing
Reporting owner signature: Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact

Filing notes and source

Key filing fact

Elvia Cowan filed Form 4 for Vaxcyte, Inc. (PCVX) on 04 Nov 2026.

Key facts

This page summarizes Elvia Cowan's Form 4 filing for Vaxcyte, Inc. (PCVX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Nov 2026, 16:52.

Change

Previous filing in this sequence was filed on 07 Oct 2026.
Current net transaction value: -$182,753.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001960048 Primary reporting owner

Cowan Elvia

Relationship: SVP, Finance & CAO
Address: C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS
Signature: Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCVX transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,000
Change %: +11%
Price: $25.92^*
Shares after: 30,860
Date: 02 Nov 2026
Ownership: Direct

PCVX transaction

Common Stock

Sale

Transaction value: -$146,687
Shares: -2,414
Change %: -7.8%
Price: $60.76
Shares after: 28,446
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1, F2

PCVX transaction

Common Stock

Sale

Transaction value: -$36,067
Shares: -586
Change %: -2.1%
Price: $61.55
Shares after: 27,860
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -3,000
Change %: -4.1%
Price: $0.000000^*
Shares after: 71,068
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price: $25.92
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.

Footnote F2

The price reported is a weighted-average price. The shares were sold at prices ranging from $60.345 to $61.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

The price reported is a weighted-average price. The shares were sold at prices ranging from $61.425 to $61.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

Stock Option is fully vested and exercisable.